bioRxiv (Cold Spring Harbor Laboratory)
May 17, 2024
Elizabeth L. Fisher, Ryan Smith, Andrew W. Corcoran et al.
2 citations
preprint
Abstract Psilocybin has shown promise as a novel pharmacological intervention for treatment of depression, where post-acute effects of psilocybin treatment have been associated with increased positive mood and decreased pessimism. Although psilocybin is proving to be effective in clinical trials for treatment of psychiatric disorders, the information processing mechanisms affected by psilocybin...
Psychiatry and Clinical Neurosciences Reports
May 16, 2024
Shunichiro Ikeda, Toshihiko Kinoshita
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various disorders, such as major depressive disorder (MDD). However, the non-medical use of these substances became rampant due to their hallucinogenic effects, leading to their classification as narcotics in numerous countries by the 1970s. Since the 1990s,...
Journal of Education, Health and Sport
May 15, 2024
Mateusz Pawlicki, Aleksandra Kłos, Karol Stachyrak et al.
Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often source of true suffering for patients and their families leading to further health issues or even dramatic outcomes resulting in death. As public awareness rises, more and more people understand risks and tend to look for help as fast as possible....
Journal of the Neurological Sciences
May 15, 2024
Emmanuelle A. D. Schindler, R Andrew Sewell, Christopher Gottschalk et al.
37 citations
In a recent randomized, double-blind, placebo-controlled study, we observed a nonsignificant reduction of attack frequency in cluster headache after pulse administration of psilocybin (10 mg/70 kg, 3 doses, 5 days apart each). We carried out a blinded extension phase to consider the safety and efficacy of repeating the pulse regimen. Eligible participants returned to receive a psilocybin pulse...
Psychopharmacology
May 14, 2024
Mazen A Atiq, Matthew R Baker, Jennifer L. Vande Voort et al.
12 citations
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight - at times, bordering on the mystical - one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have found strong correlations between the...
Psychiatric News
May 10, 2024
Terri D’arrigo
Back to table of contents Next article Clinical & ResearchFull AccessCalls to Poison Centers Involving Psilocybin Rising in YouthTerri D'ArrigoTerri D'ArrigoPublished Online:10 May 2024https://doi.org/10.1176/appi.pn.2024.06.6.2AbstractDecriminalization, legalization of psilocybin likely play roles in both increased exposure and poisoning.Getty Images/iStock/YarphotoSince 2019, calls to U.S....
ACS Medicinal Chemistry Letters
May 8, 2024
Robert B. Kargbo
2 citations
This Patent Highlight explores advancements in pharmacology, focusing on the novel delivery and application of psychoactive substances. It highlights the development of transdermal formulations for psychoactive alkaloids, neuroenhancement techniques to augment emotional responses, and the intravenous infusion of psilocybin or psilocin for various therapeutic purposes. Additionally, it delves...
Psychedelic Medicine
May 8, 2024
Susanna Myers, John Guy, Anthony L. Back et al.
7 citations
For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice guidelines that aimed to describe facilitator use of touch in a way that is ethical, supportive, and minimizes harm. In our first three retreats, however, we had two unexpected experiences with touch that led us to iterate our initial guidelines into...
Journal of Psychoactive Drugs
May 7, 2024
Sandeep M. Nayak, Sydney H White, Samantha Hilbert et al.
18 citations
Recent studies suggest psychedelic use may be associated with changes in a variety of beliefs or belief-like states, including increased 1) mind perception, 2) non-naturalistic beliefs, and 3) Atheist-Believer status (e.g. believer, agnostic, or nonbeliever). We conducted a prospective longitudinal study among participants (N = 657) who planned to have a psilocybin experience outside a...
BMJ
May 4, 2024
2 citations
The journal and the authors are investigating the problem.The study analysed data from randomised trials of psilocybin for the treatment of depression in adults.A methodological concern has been raised about an error in the calculation of standardised mean differences.This is likely to have overestimated the benefits of psilocybin.The authors are reviewing and responding to the error and its...
Brain
May 4, 2024
Jérôme Jeanblanc, Romain Bordy, Grégory Fouquet et al.
10 citations
Abstract The use of psilocybin to treat alcohol use disorder is very promising, but its mechanisms of action remain poorly understood. We combined behavioural, pharmacological and gene expression analyses to decipher the mechanisms of action of psilocybin, for the first time, when injected into the brain. Male Long Evans rats underwent chronic operant ethanol self-administration before testing...
Psychedelic Medicine
May 3, 2024
correction
[This corrects the article DOI: 10.1089/psymed.2022.0002.].
May 2, 2024
Hanna Brancaccio
Introduction: Substance use disorder (SUD) and alcohol use disorder (AUD) are major public health crises, affecting millions of Americans. Current treatment options include behavioral therapies and medications. In this review, we explored psilocybin’s efficacy in treating SUD and AUD. Methods: Key terms were used to search databases to identify articles that addressed psilocybin in the...
Social Work
May 2, 2024
Claire Parker, Bethany Wood
2 citations
Abstract This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD,...
Headache: The Journal of Head and Face Pain
May 1, 2024
Jonathan A. Leighton, Cyril Petignat, Brian E. Mcgeeney
2 citations
Plain Language Summary A suicidal patient with Short‐lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing (SUNCT) whose excruciating condition did not respond to various treatments discovered that ayahuasca, a psychoactive concoction used by indigenous populations of South America, caused his attacks to cease entirely. Inhaled N , N ‐dimethyltryptamine (DMT),...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
May 1, 2024
Mark A. Geyer
30 citations
Classical serotonergic psychedelics such as lysergic acid diethylamide or the naturally occurring compounds psilocybin and mescaline produce profound changes in mood, thought, intuition, sensory perception, the experience of time and space, and even the experience of self. Research examining psychedelic compounds has had a complex and turbulent evolution. Many cultures throughout the world have...
Drug and Alcohol Dependence
May 1, 2024
Joseph J Palamar, Nicole D. Fitzgerald, Thomas H Carr et al.
9 citations
Psilocybin, the principle psychoactive component in "shrooms", is regaining acceptance in therapeutic settings, leading to media coverage of medical benefits associated with use. Possession is also becoming increasingly decriminalized throughout the United States. There is a lack of data on prevalence of shroom use, but trends in law enforcement seizure data can provide one indicator of shroom...
Journal of Psychopharmacology
May 1, 2024
Arman Shafiee, Razman Arabzadeh Bahri, Mohammad Ali Rafiei et al.
21 citations
Retracted
Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within the brain. Integrated review and analysis of different studies in this field. A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023. Eligibility...
Journal of Adolescent Health
May 1, 2024
Rita Farah, Abigail F Kerns, Austin C Murray et al.
18 citations
We describe trends in psilocybin exposures among adolescents and young adults as reported to US poison centers over the past decade. We queried the National Poison Data System for cases involving psilocybin during January 1, 2013-December 31, 2022. Persons aged 13-25 years were included. We examined exposures to psilocybin by demographics, clinical effects, level of care, and medical outcome....
Psychiatry Research
May 1, 2024
Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al.
48 citations
Psychotherapies assisted by psychedelic substances have shown promising results in the treatment of psychiatric disorders. The aim of this systematic review and meta-analysis was to evaluate safety data in human subjects. We carried out a search on MEDLINE, Embase and PsycINFO databases between 2000 and 2022. Standardized mean differences between different dose ranges and between acute and...